<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Sebastian Azar on Medium]]></title>
        <description><![CDATA[Stories by Sebastian Azar on Medium]]></description>
        <link>https://medium.com/@Sebastian_Azar?source=rss-764d1a0e5a13------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*EFZo96PeJgldhHzPnCLn4g.png</url>
            <title>Stories by Sebastian Azar on Medium</title>
            <link>https://medium.com/@Sebastian_Azar?source=rss-764d1a0e5a13------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sat, 21 Nov 2026 03:51:05 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@Sebastian_Azar/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Innovation in the Netherlands: The AI Toolkit Powering Europe’s Most Agile Ecosystem]]></title>
            <link>https://medium.com/@Sebastian_Azar/innovation-in-the-netherlands-the-ai-toolkit-powering-europes-most-agile-ecosystem-598e91f335c6?source=rss-764d1a0e5a13------2</link>
            <guid isPermaLink="false">https://medium.com/p/598e91f335c6</guid>
            <category><![CDATA[netherlands]]></category>
            <category><![CDATA[ai]]></category>
            <category><![CDATA[startup]]></category>
            <dc:creator><![CDATA[Sebastian Azar]]></dc:creator>
            <pubDate>Wed, 22 Apr 2026 09:37:37 GMT</pubDate>
            <atom:updated>2026-04-22T09:37:37.349Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*UYGD-Q3g5x6A7xiXlCeneg.png" /></figure><p>The Netherlands has quietly become one of Europe’s most advanced innovation hubs — not by scale, but by <strong>speed, collaboration, and applied intelligence</strong>. With over <strong>800+ AI startups, €2.8B in annual investment, and strong public-private funding programs like AiNed</strong>, the country punches far above its weight in global innovation.</p><p>From Amsterdam’s AI SaaS startups to Eindhoven’s deep-tech hardware ecosystem, Dutch innovation is not theoretical — it is operational, commercial, and fast-moving.</p><p>At the center of this momentum is a new stack: <strong>AI tools that reduce time-to-market, compress decision cycles, and amplify individual output</strong>.</p><p>Below are the <strong>5 AI tools innovators in the Netherlands should be using right now</strong> — not generic picks, but tools aligned with how the Dutch ecosystem actually builds.</p><h3>1. ChatGPT — The Strategic Thinking Layer</h3><p>In the Dutch innovation ecosystem, speed matters more than perfection.</p><p>ChatGPT has become the <strong>default “thinking partner”</strong> for founders, product managers, and consultants across the Netherlands.</p><h3>Why it matters locally:</h3><ul><li>Rapid prototyping aligns with the <strong>Lean Startup mindset</strong> common in Dutch startups</li><li>Used for <strong>market sizing, pitch drafting, and product specs</strong></li><li>Enables small teams to operate like larger organizations</li></ul><h3>Real use case:</h3><p>Dutch startups use AI copilots to:</p><ul><li>Draft investor decks in hours</li><li>Simulate customer personas</li><li>Build first MVP logic before writing code</li></ul><p>👉 In a country where <strong>average AI ROI can be achieved in ~11 months</strong>, tools that compress thinking cycles are critical.</p><h3>2. UbiOps — From Prototype to Production</h3><p>One of the biggest bottlenecks in AI isn’t building models — it’s deploying them.</p><p>That’s where UbiOps, a Dutch-born platform, becomes essential.</p><h3>Why it matters:</h3><ul><li>Designed for <strong>European compliance (GDPR-first)</strong></li><li>Allows startups to deploy models without managing infrastructure</li><li>Widely used by <strong>hundreds of European companies</strong></li></ul><h3>Strategic advantage:</h3><p>In the Netherlands, where regulation and data governance are strict, <strong>deployment speed + compliance = competitive edge</strong>.</p><h3>When to use it:</h3><ul><li>Scaling AI MVPs into real products</li><li>Running APIs for AI-powered features</li><li>Managing multiple models in production</li></ul><h3>3. Synthesia — Content at Scale</h3><p>The Netherlands is a global leader in <strong>marketing tech and digital communication</strong>, and Synthesia (Dutch-founded) is one of its breakout AI companies.</p><h3>What it does:</h3><ul><li>Turns text into <strong>AI-generated videos with avatars</strong></li><li>Eliminates need for filming, editing, or studios</li></ul><h3>Why innovators need it:</h3><ul><li>Sales teams create personalized demos instantly</li><li>Startups produce <strong>investor-ready explainer videos</strong></li><li>Corporates scale internal training across languages</li></ul><h3>Bigger trend:</h3><p>Marketing &amp; AdTech is one of the <strong>fastest-growing AI sectors in the Netherlands (+55% YoY)</strong>.</p><p>👉 If you’re not using AI-generated content, you’re already behind in this market.</p><h3>4. Notion AI — Operational Intelligence</h3><p>Dutch innovation culture is highly structured: clear documentation, alignment, and execution discipline.</p><p>Notion AI fits perfectly into this.</p><h3>Why it works:</h3><ul><li>Combines <strong>knowledge management + AI assistance</strong></li><li>Used for:</li><li>Product roadmaps</li><li>Meeting summaries</li><li>Internal wikis</li></ul><h3>Dutch-specific advantage:</h3><p>In ecosystems like Amsterdam and Utrecht, where <strong>cross-functional collaboration is the norm</strong>, Notion AI becomes the <strong>single source of truth enhanced by AI</strong>.</p><h3>Result:</h3><ul><li>Faster onboarding</li><li>Better decision documentation</li><li>Less operational chaos</li></ul><h3>5. Nebius AI Cloud — Infrastructure Sovereignty</h3><p>Europe is increasingly focused on <strong>AI sovereignty</strong>, and Dutch innovators are no exception.</p><p>Nebius represents a new category:<br> 👉 European AI infrastructure competing with AWS and Google.</p><h3>Why this matters in NL:</h3><ul><li>Increasing demand for <strong>EU-based AI hosting</strong></li><li>Strategic push to reduce dependency on US providers</li><li>Major enterprise contracts driving adoption</li></ul><h3>When to use:</h3><ul><li>Training large models</li><li>Running GPU-heavy workloads</li><li>Building AI-native products</li></ul><h3>Strategic insight:</h3><p>The next wave of Dutch innovation won’t just use AI — it will <strong>own the infrastructure layer</strong>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=598e91f335c6" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The New Triad of Digital Strategy: AI, Workflow Design, and Trust]]></title>
            <link>https://medium.com/@Sebastian_Azar/the-new-triad-of-digital-strategy-ai-workflow-design-and-trust-8203c91e96b9?source=rss-764d1a0e5a13------2</link>
            <guid isPermaLink="false">https://medium.com/p/8203c91e96b9</guid>
            <dc:creator><![CDATA[Sebastian Azar]]></dc:creator>
            <pubDate>Fri, 20 Jun 2025 08:28:47 GMT</pubDate>
            <atom:updated>2025-06-20T08:28:47.009Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*bClwTRxgVPFvywMOBz2mcw.png" /></figure><p>We’ve entered an era where technology is no longer the enabler — it’s the environment. Businesses that once talked about “digital transformation” as a future goal are now swimming in it, whether they’re prepared or not. Amid this digital current, three forces shape whether a company merely adapts or leads: <strong>AI</strong>, <strong>workflow design</strong>, and <strong>digital trust</strong>.</p><h3>1. AI is No Longer Optional — It’s Operational</h3><p>Artificial Intelligence, particularly in the form of machine learning and large language models, is not a buzzword. It’s infrastructure. If you’re still thinking of AI as something to “explore,” you’re behind. From process automation and knowledge retrieval to predictive diagnostics and creative co-pilots, AI is becoming embedded in how work happens.</p><p>But real value comes from <strong>purposeful integration</strong>, not blind adoption. The question is no longer “What can AI do?” but “How will it help people do what they already do, better?”</p><h3>2. Workflow Design is Strategy</h3><p>Workflow used to be considered an operational afterthought — a technical detail for process managers to optimize. Today, <strong>workflow is where strategy becomes reality</strong>.</p><p>A good idea, poorly executed through disjointed systems, dies in friction. But smart workflow design — human-centered, data-informed, and AI-augmented — turns insight into action. It builds resilience, clarity, and speed.</p><p>Ask yourself: Are your teams working around your systems or with them? Your workflows are either enabling intelligence or absorbing it.</p><h3>3. Digital Trust is the Ultimate Currency</h3><p>None of this matters if users — employees, partners, or customers — don’t trust your systems. AI needs data. Workflows need transparency. People need control.</p><p>Trust is not a <em>nice to have</em>; it’s the foundation of digital interaction. In the age of AI and automation, trust becomes <strong>transactional infrastructure</strong> — quietly enabling or invisibly blocking adoption.</p><p>A powerful example comes from the <strong>UK’s National Health Service (NHS)</strong> and its 2019 partnership with <strong>DeepMind</strong>, Google’s AI subsidiary. The initiative aimed to use AI to detect acute kidney injury by analyzing patient data. Technically, the pilot showed promise — but the public backlash was swift and severe when it emerged that <strong>1.6 million patient records had been shared without proper patient consent</strong>.</p><p>The UK’s Information Commissioner’s Office (ICO) ruled that the data sharing had <strong>violated data protection laws</strong>. Despite DeepMind’s intentions to improve patient outcomes, the absence of clear <strong>data governance, transparency, and patient control mechanisms</strong> damaged public trust — and ultimately stalled broader AI implementation across the NHS.</p><blockquote><em>“The price of progress cannot be blind trust.” — </em>Elizabeth Denham, UK Information Commissioner</blockquote><p>(<strong>Source</strong>: ICO. <a href="https://ico.org.uk/about-the-ico/news-and-events/news-and-blogs/2017/07/royal-free-google-deepmind-trial-failed-to-comply-with-data-protection-law/">“Royal Free — Google DeepMind trial failed to comply with data protection law.”</a> July 2017)</p><p>This case illustrates a universal truth: <strong>even the most powerful AI is useless if users opt out or organizations are forced to pause due to public or regulatory pressure</strong>.</p><h3>What Builds Digital Trust?</h3><ul><li><strong>Explainability</strong>: Users need to understand how decisions are made.</li><li><strong>Consent and control</strong>: Data subjects must feel agency, not surveillance.</li><li><strong>Security and governance</strong>: Frameworks must be auditable, adaptable, and legally defensible.</li></ul><p>In the next evolution of AI-powered systems, trust must be <strong>designed in</strong> — not bolted on.</p><h3>What’s Next?</h3><p>Over the coming months, I’ll be publishing more on:</p><ul><li>Architecting AI-ready workflows in regulated environments</li><li>Designing systems that scale human judgment, not just automate it</li><li>Building trust through explainable AI and clear UX patterns</li></ul><p>If you’re a builder, a leader, or someone asking “how do we make this actually work?” — I invite you to follow along.</p><p><strong>By Sebastian Azar</strong><br> <em>Written with help from AI (ChatGPT) — because I believe the tools we write about should be the ones we write with.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8203c91e96b9" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Apple Vision Pro and the Future of Decentralized Science: How the M5 Chip Will Revolutionize…]]></title>
            <link>https://medium.com/@Sebastian_Azar/apple-vision-pro-and-the-future-of-decentralized-science-how-the-m5-chip-will-revolutionize-58cdbeda0a2e?source=rss-764d1a0e5a13------2</link>
            <guid isPermaLink="false">https://medium.com/p/58cdbeda0a2e</guid>
            <category><![CDATA[apple-vision-pro]]></category>
            <category><![CDATA[innovation]]></category>
            <category><![CDATA[ai-spatial-computing]]></category>
            <category><![CDATA[pharma-virtual-reality]]></category>
            <category><![CDATA[desci]]></category>
            <dc:creator><![CDATA[Sebastian Azar]]></dc:creator>
            <pubDate>Wed, 06 Nov 2024 11:49:12 GMT</pubDate>
            <atom:updated>2024-11-06T14:56:38.578Z</atom:updated>
            <content:encoded><![CDATA[<h3>Apple Vision Pro and the Future of Decentralized Science: How the M5 Chip Will Revolutionize Research and Collaboration</h3><p>The field of science is undergoing a seismic shift, as decentralized science (DeSci) continues to challenge traditional research methods and frameworks. At the intersection of these innovations lies Apple’s <strong>Vision Pro</strong>, a mixed-reality (MR) headset that promises to reshape how we interact with information, collaborate on research, and engage in scientific discovery. With the anticipated <strong>M5 chip</strong> powering the <strong>Apple Vision Pro 2</strong>, this device is primed to accelerate the decentralized movement, providing unprecedented opportunities for researchers, innovators, and scientists.</p><figure><img alt="AI spatial computing to be the main selling point for new M5-powered Vision Pro; new Apple suppliers like Zhaowei in focus" src="https://cdn-images-1.medium.com/max/1024/1*bQOKE8h87L0M_brRqBImTQ.jpeg" /></figure><p>In this article, we’ll explore how <strong>Apple Vision Pro</strong> is set to disrupt the world of decentralized science (DeSci), the transformative role the <strong>M5 chip</strong> will play in this evolution, and how it will fundamentally alter the way science is conducted, shared, and understood.</p><h3>What is Decentralized Science (DeSci)?</h3><p>Before diving into the specifics of the <strong>Apple Vision Pro</strong> and its role in DeSci, it’s important to understand what decentralized science (DeSci) means. <strong>DeSci</strong> refers to a new approach to conducting scientific research, powered by blockchain technology, decentralized networks, and open-source principles. The idea behind DeSci is to democratize the scientific process, making research more transparent, accessible, and collaborative. It challenges traditional top-down systems, such as centralized funding models, academic institutions, and publishers, and instead empowers individual researchers and communities to contribute to scientific discovery.</p><p>Key elements of DeSci include:</p><ul><li><strong>Open Access</strong>: Researchers are increasingly sharing data, findings, and methodologies openly, bypassing the paywalls of traditional scientific journals.</li><li><strong>Tokenization</strong>: Blockchain technology allows researchers to tokenize intellectual property and research outcomes, making it easier to track contributions, incentivize participation, and fund projects through decentralized finance (DeFi).</li><li><strong>Collaboration and Crowdsourcing</strong>: DeSci fosters global collaboration by connecting researchers from diverse fields, allowing for crowdsourced problem-solving and funding models that don’t rely on traditional institutions.</li></ul><p>The integration of <strong>Apple Vision Pro</strong> into the DeSci ecosystem could provide the necessary tools to accelerate this movement, facilitating both the virtual and real-world collaboration needed to address complex scientific challenges.</p><h3>Apple Vision Pro: A Leap Towards Immersive, Collaborative Science</h3><p>The <strong>Apple Vision Pro</strong> is Apple’s ambitious entry into the world of <strong>mixed reality</strong> (MR), combining both <strong>augmented reality</strong> (AR) and <strong>virtual reality</strong> (VR) technologies. This device is designed to seamlessly blend the digital and physical worlds, offering immersive experiences that go beyond simple media consumption or entertainment. Apple envisions the Vision Pro as a powerful tool for productivity, creativity, and collaboration, making it an ideal candidate for transforming how scientists and researchers approach their work.</p><p>For decentralized science to thrive, collaboration and access to cutting-edge tools are essential. The <strong>Vision Pro</strong> is perfectly positioned to enable this, offering the following potential uses for DeSci:</p><h4>1. Real-Time Virtual Collaboration</h4><p>One of the most powerful features of the <strong>Vision Pro</strong> is its ability to facilitate real-time collaboration in virtual environments. Scientists and researchers can come together from around the world in a shared, immersive virtual space, accessing research data, 3D models, or simulations in real time.</p><p>Imagine a team of molecular biologists, data scientists, and chemists working together to design a new drug. Using <strong>Vision Pro</strong>, they could virtually meet, interact with molecular simulations in 3D, manipulate and adjust parameters in real time, and share data across a common virtual workspace. This could eliminate the need for physical labs or limited research facilities, breaking down geographical barriers and allowing for collaboration on an unprecedented scale.</p><h4>2. Interactive Data Visualization</h4><p>The Vision Pro’s mixed-reality capabilities allow for advanced <strong>data visualization</strong>, which is particularly important for scientists who need to interpret and manipulate complex datasets. Whether it’s viewing DNA sequences, astronomical data, or climate models, the <strong>Vision Pro</strong> can present information in interactive 3D spaces, allowing researchers to manipulate and analyze data intuitively.</p><p>This type of immersive data visualization is crucial for fields such as genomics, where understanding complex genetic relationships or visualizing protein structures can be difficult without interactive tools. Rather than viewing static graphs or 2D representations, researchers can “walk through” datasets, zooming in and out, and identifying patterns or anomalies that may not be immediately apparent.</p><h4>3. Open-Source Data and Community Engagement</h4><p>DeSci emphasizes transparency, and the <strong>Vision Pro</strong> could be the gateway for researchers to share their data and discoveries in new ways. With immersive VR and AR, scientists could present their findings in interactive public forums or virtual conferences, where anyone in the community can join the conversation, ask questions, and contribute to the discussion.</p><p>This can further decentralize science by making research findings more accessible to anyone, anywhere, and opening the door for global collaboration. Instead of waiting for a journal publication or grant approval, scientists can immediately share their work in real-time with a worldwide audience.</p><h4>4. Virtual Labs and Simulation-Based Learning</h4><p>In many scientific disciplines, conducting experiments requires expensive equipment and extensive lab space. The <strong>Vision Pro</strong> could help bridge this gap by offering virtual laboratories where students, researchers, or hobbyists can simulate experiments, test hypotheses, and visualize scientific phenomena in a fully immersive environment.</p><p>The virtual lab concept could democratize access to scientific tools, particularly for institutions and individuals with limited resources. This would lower the barrier to entry for aspiring researchers in developing countries or remote regions, promoting inclusivity and collaboration on a global scale.</p><h3>The M5 Chip: Powering the Future of Decentralized Science</h3><p>As Apple continues to innovate with its hardware, the <strong>M5 chip</strong> in the next generation of the <strong>Vision Pro 2</strong> will likely be the game-changer that elevates these possibilities. The <strong>M5 chip</strong>, following in the footsteps of the highly successful <strong>M1</strong> and <strong>M2</strong> chips, is expected to deliver exponential improvements in processing power, energy efficiency, and AI capabilities. Here’s how the M5 chip will make a significant impact on DeSci and scientific collaboration:</p><h4>1. Enhanced Performance for Real-Time Collaboration</h4><p>The M5 chip will likely be a significant leap in processing power, particularly in handling the complex computations required for real-time scientific collaboration. The ability to process massive datasets, perform AI-driven analysis, and render 3D models in real-time without lag will be critical for researchers collaborating in virtual spaces.</p><p>Whether it’s rendering molecular simulations, creating large-scale interactive models, or running real-time analysis of scientific experiments, the M5 chip will provide the raw power needed to ensure that these tasks happen seamlessly, without interruptions. This is particularly important for DeSci projects that rely on live feedback, crowd-sourced data analysis, or iterative simulations.</p><h4>2. Advanced AI Capabilities for Decentralized Research</h4><p>With the integration of AI cores in the M5 chip, Apple Vision Pro will bring advanced machine learning and data processing capabilities to scientific research. AI can assist in everything from automating repetitive tasks to providing predictive models based on available data. For decentralized science, AI could help analyze data across a distributed network, facilitating better decision-making in the absence of centralized oversight.</p><p>Imagine an AI-powered research assistant that learns from a decentralized pool of global data, suggesting new research directions or uncovering patterns that may not be immediately apparent to individual researchers. This could accelerate innovation and the development of new scientific breakthroughs by enabling more efficient exploration of vast datasets.</p><h4>3. Decentralized Computing Power with Edge AI</h4><p>Another important feature of the M5 chip is its ability to support <strong>edge computing</strong>, which is a key enabler of decentralized science. Instead of relying on centralized cloud servers to process data, the M5 chip will allow <strong>Vision Pro 2</strong> users to process data locally, reducing latency and improving efficiency. This is especially useful for projects involving large-scale simulations or real-time collaboration, where data needs to be processed quickly to maintain an immersive experience.</p><p>Moreover, decentralized research projects often rely on computing power from distributed networks. With the <strong>M5 chip</strong> on the Vision Pro 2, researchers can contribute their computing power to a decentralized network, processing and analyzing data locally, contributing to the collective effort without the need for centralized infrastructure.</p><h3>Impact on the Future of Science</h3><p>The convergence of Apple Vision Pro, the M5 chip, and decentralized science will redefine how research is conducted and shared. Here’s how:</p><h4>1. Global Scientific Collaboration</h4><p>With decentralized science, anyone, anywhere, can contribute to scientific discovery. The <strong>Vision Pro</strong> will break down geographical barriers, providing a virtual meeting ground for researchers worldwide. As the device enables more efficient, immersive collaboration, it will foster interdisciplinary and cross-institutional partnerships that would have been impossible under traditional models.</p><h4>2. Open Science Revolution</h4><p>Decentralized science is fundamentally built on the principle of openness. By using Apple’s <strong>Vision Pro</strong> and M5-powered features, scientists can present their findings in innovative ways, share research data more freely, and directly engage with communities. Open-access research and decentralized peer review will become the norm, rather than the exception.</p><h4>3. Accelerated Innovation</h4><p>The <strong>Vision Pro</strong> coupled with the M5 chip’s computational power will provide researchers with new tools for data analysis, simulation, and collaboration. This will enable faster problem-solving, reduced time-to-market for research findings, and an overall acceleration in scientific innovation.</p><h3>Conclusion: A New Era of Scientific Discovery</h3><p>The future of decentralized science (DeSci) is bright, and the <strong>Apple Vision Pro 2</strong>, powered by the <strong>M5 chip</strong>, is poised to be a cornerstone of this transformation. By combining immersive virtual and augmented reality with powerful AI and computing capabilities, <strong>Apple Vision Pro</strong> is set to unlock new ways for researchers and scientists to collaborate, share, and innovate in.</p><p>#DecentralizedScience, #AppleVisionPro, #M5Chip, #SciTechInnovation, #ImmersiveCollaboration, #AIinScience, #FutureOfResearch, #VirtualLab, #OpenScience, #MixedRealityScience</p><p><em>Disclaimer: The views, opinions, and analysis expressed are those of the author Sebastian Azar, and do not reflect or represent any policy or position of his employer, private or public institutions.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=58cdbeda0a2e" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[A DeSci patient recruitment platform?]]></title>
            <link>https://medium.com/@Sebastian_Azar/a-desci-patient-recruitment-platform-ffd3686f0030?source=rss-764d1a0e5a13------2</link>
            <guid isPermaLink="false">https://medium.com/p/ffd3686f0030</guid>
            <category><![CDATA[medical-data]]></category>
            <category><![CDATA[pharma]]></category>
            <category><![CDATA[patient-recruitment]]></category>
            <category><![CDATA[clinical-studies]]></category>
            <dc:creator><![CDATA[Sebastian Azar]]></dc:creator>
            <pubDate>Wed, 03 Jan 2024 07:30:25 GMT</pubDate>
            <atom:updated>2024-01-03T07:30:25.160Z</atom:updated>
            <content:encoded><![CDATA[<h3>Data Lake launches Consentify</h3><p>Unlocking the potential of medical data is crucial, yet the current landscape of patient recruitment and data access is plagued by inefficiencies, is intransparent or even unethical. The fragmentation within research organizations, each building its own hermetic referral network, leaves the majority of healthcare providers excluded.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*48rXe-RVnb5zytuFzkpLsQ.png" /></figure><p>Researchers grapple with friction in tracking referrals, compensation, and ensuring participant engagement, leading to a scarcity of participants in research projects. Fear, fueled by compliance and data privacy concerns, deters many providers from participating in patient recruitment programs for data acquisition.</p><p>As a consequence, nearly 80% of clinical studies experience delays, and the cost of patient recruitment comprises a staggering 40% of overall clinical trial expenses. With recruitment costs ranging up to $5,000 per patient, the global challenge of patient recruitment for clinical trials and data acquisition has surged to a $100 billion problem.</p><p>Data Lake was founded in 2019 by Wojciech Sierocki and Ligia Kornowska, two Medical Doctors and entrepreneurs who felt the need to revolutionize the antiquated system of patients’ data collection to fully unlock the potential of medical research and save lives.</p><p>Since then, Data Lake has engaged with esteemed institutions like the EU Commission and collaborated with industry leaders, including top 10 global pharma companies, medical AI startups, researchers, medical professionals, various healthcare entities and DeSci projects. As the company continuously gathered feedback about the problem of medical data collection, the approach has changed to solving the problem several times, always focussing on ensuring transparency and patient centricity.</p><p>In the initial phase, Data Lake empowered the Polish “Podaruj Dane” (<a href="https://beincrypto.com/learn/donate-crypto/">Donate</a> Your Data) Foundation, providing the necessary technology to successfully collect tens of thousands of consents from Polish patients — an initiative that continues to make a positive impact today.</p><p>Then, earlier in 2023, Data Lake understood that no matter how hard to try, the effort to unlock medical data by themselves was never going to be enough to feed the global demand for data needed for the research of new drugs and treatments. In pursuit of a more impactful approach the company decided to implement more decentralized and inclusive approach.</p><p>Data Lake decided to improve the platform to collect consents for medical data and to make it available for and customizable by thousands of researchers, start-ups and pharma companies worldwide, and also made so that this new platform integrates token LAKE.</p><p>The pricing is fairly good, especially for those Pharma initiatives in early stage and lacking a fluent funding stream.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*B1sT3TNVt4eg3dKUHtWAfg.png" /></figure><p>This piece is part of the articleUnlocking Medical Research: Data Lake launches Consentify</p><ol><li><a href="https://beincrypto.com/unlocking-medical-research-data-lake-launches-consentify-the-first-desci-patient-recruitment-platform/">https://beincrypto.com/unlocking-medical-research-data-lake-launches-consentify-the-first-desci-patient-recruitment-platform/</a></li></ol><p><em>Disclaimer: The views, opinions, and analysis expressed are those of the author Sebastian Azar, and do not reflect or represent any policy or position of his employer, private or public institutions.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=ffd3686f0030" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Blockchain-based biotech: is this a viable financing method?]]></title>
            <link>https://medium.com/@Sebastian_Azar/blockchain-based-biotech-is-this-a-viable-financing-method-32386709139e?source=rss-764d1a0e5a13------2</link>
            <guid isPermaLink="false">https://medium.com/p/32386709139e</guid>
            <dc:creator><![CDATA[Sebastian Azar]]></dc:creator>
            <pubDate>Mon, 16 Oct 2023 18:59:08 GMT</pubDate>
            <atom:updated>2024-01-03T13:48:20.034Z</atom:updated>
            <content:encoded><![CDATA[<p>At a time when biotechs are scrambling to raise funds, a new way for startups to secure investments is emerging: leveraging cryptocurrency. The motive behind decentralized financing seems pretty ambitious — to democratize funding in healthcare. But does it live up to the hype?</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/544/1*ytRTxrxOCuLG9Fy5JxlLDA.png" /></figure><p>With VitaDAO — a decentralized collective that funds early-stage startups looking to move up in the longevity space — launching Matrix Biosciences, a biotech developing treatments for age-related disorders, the biotech industry may be warming up to the idea of cryptocurrency-based financing.</p><p>“The emerging trend of cryptocurrency funding in biotech is driven by the need for more flexible and innovative financing options in an industry where traditional funding routes are often outdated and focused on established projects,” said Alex Dobrin, awareness steward at VitaDAO. “Cryptocurrency and community-funded financing provide opportunities to support cutting-edge research and reduce risk.”</p><p>As crowdfunding gets a blockchain makeover, how exactly does it work?</p><h3>How do decentralized autonomous organizations operate?</h3><p>Decentralized Autonomous Organizations (DAOs) are open, member-driven entities that operate through smart contracts on a blockchain, explained Israel Mirsky, co-founder of decentralized community Pharma DAO. A smart contract is a computer program that is stored on a blockchain that automates the actions required in an agreement or contract.</p><p>“The premise of a DAO is to have a decentralized governance structure where decisions are made collectively by its members,” said Mirsky.</p><p>Funding for <a href="https://www.labiotech.eu/best-biotech/dao-web3-biotech-top/">DAOs</a> often comes from individuals or entities interested in the DAO’s goals and mission. The level of public interest in a DAO’s goals can significantly impact the amount of funding it receives, as more interest can lead to more contributions, according to Mirsky.</p><p>Funding by the DAO is driven by a combination of domain experts and public attention, he explained. In the case of biotech proposals, they are complex, and so, domain experts play a crucial role in these DAOs by vetting projects and investments. These experts aim to ensure that the DAO’s funds are allocated to promising endeavors.</p><p>Upon vetting the investments, the DAO members get to vote using tokens that allow them to go for or against a proposal. In exchange for voting tokens, they contribute funds to the DAO. These tokens are significant in being able to participate in key decision-making processes within the DAO.</p><p>“The blend of expert guidance and democratic voting aims to balance informed decision-making with decentralized governance, transparency, and public accountability,” said Mirsky.</p><h3>U.K. biotech project receives cryptocurrency funding</h3><p>This way, companies can tap into a wider pool of investors. One of the first biotech projects in the U.K. to be fueled by cryptocurrency and blockchain technology was undertaken by Newcastle University. The $285,000 <a href="https://from.ncl.ac.uk/funding-science-through-blockchain-technology-and-cryptocurrencies">project</a> funded by VitaDAO, aims to identify novel bioactive autophagy inducers. Autophagy inducers trigger cellular pathways that can help the cells clean out or recycle damaged components in cells. This is believed to help combat age-related and neurodegenerative diseases.</p><p>What took around four weeks to close the deal — from submitting the proposal to contract execution — the process of securing the funds was based on a number of things. DAOs look at how feasible the project is, its innovative value, and whether it tallied with the DAOs, where, in the case of the Newcastle University project, it had to align with VitaDAO’s focus on the longevity industry.</p><p>With the ​​global decentralized finance market size valued at more than $13 billion in 2022, according to a <a href="https://www.grandviewresearch.com/industry-analysis/decentralized-finance-market-report">report</a> by Grand View Research, the <a href="https://www.labiotech.eu/in-depth/equity-crowdfunding-biotech-startups/">biotech industry</a> may be dipping into the pot as of late. Last year, Molecule, a science platform where research projects can obtain funding through a DAO, raised $13 million in seed funding. As a part of what is now known as the DeSci — short for decentralized science — movement, it has catalyzed financing for 12 projects worth a total of nearly $2 million, so far. The major DAOs it collaborates with include VitaDAO — which has contributed more than $1 million — AthenaDAO, specializing in reproductive health, HairDAO, focused on hair loss, ValleyDAO for the field of synthetic biology, PsyDAO in psychedelics, and CryoDAO specializing in cryopreservation.</p><p>Molecule has created a non-fungible token (NFT) — a kind of digital identifier that is recorded on a blockchain that is used to validate ownership of something — framework wherein details of the intellectual property (IP) are stored digitally. Molecule’s marketplace, Molecule Discovery is a space for researchers seeking funding, to upload their projects, negotiate licensing agreements, and be taken notice by DAOs who could potentially support their projects.</p><h3>Decentralized funding provides patient advocacy</h3><p>One of the perks that could drive blockchain technology into the biopharma funding space is the ability for patients to gain more agency in the way drugs are developed. According to a <a href="https://www.nature.com/articles/s41587-022-01459-z">report</a> by Nature, a platform like Molecule looks to be more transparent with those who are most likely to benefit from the medical discoveries that are being funded, and leveraging DAOs to distribute the responsibility for funding novel treatments and share the risks associated with them.</p><p>Through DAO communities and by vetting the investments that are made, patients would be able to attain access to a drug that they need, Paul Kohlhaas, the co-founder of Molecule, told Nature. In a way, they get to have a say in which drugs move from bench to bedside. Moreover, if a person who is diagnosed with a certain disease participates in a DAO that funds multiple projects related to a cure for said disease, the patient would co-own the IP, just like how a pharmaceutical company would own IP. This practice of sharing IP gives patients agency, and allows them to vote on the terms on which a project is licensed.</p><p>To add to that, Mirsky explained that DAOs promote democratic funding. “Traditional funding routes for biotech companies often involve venture capital firms, grants, or IPOs, which can be lengthy, competitive, and restrictive. Crucially, the selection of projects tends to focus on those entrants that are likely to result in blockbuster drugs, said Mirsky. “Unfortunately, because of wildly misaligned incentives and massive cost bases for large pharmaceutical companies, drugs need to pay back $2 billion+ per year in order to be worth pursuing. This means projects that would be significantly impactful for public health but wouldn’t hit that mark — because they are off-patent, for instance — are often passed over.”</p><p>“By leveraging blockchain technology, biotech projects can secure funding through DAOs or other decentralized financing methods, enabling a broader range of investors to contribute. Furthermore, the transparency and accountability inherent in blockchain technology can create a trusted environment for investors.”</p><p>Echoing Mirsky’s thoughts, Dobrin believes that decentralized financing is “setting a new standard for scientific research” and “making it more accessible via the DAO model.” Dobrin thinks that this could pivot research in fields like women’s health and take on overlooked diseases, as well as boost patient advocacy.</p><p>Now with the Pfizer-backed spinout Matrix Biosciences, led by the University of Rochester in the U.S., bagging seed funding of $300,000, VitaDAO’s position takes center stage within the biopharma DAO sector. Based on the science that mole rats, which have a lifespan of more than 10 times that of normal rats, are cancer resistant because they have plenty of hyaluronic acid in their tissues, the startup’s research has found that transgenic mice expressing naked mole rat hyaluronan synthase gene (NHAS2) have fewer tumors, improved health, and live 10% longer than rats without the transgene. So, the company is taking its research a step further by developing a class of small molecules to modulate the enzyme hyaluronidase for cancer treatment.</p><h3>Can regulatory concerns push biotechs away from cryptocurrency?</h3><p>However, it’s not to say that this mode of fundraising doesn’t have its setbacks. Like most investments, decentralized financing is regarded as a risk. And although cryptocurrency has been up and running for more than a decade now, it is still in its early days compared to conventional and more established investment methods. Therefore, regulatory risks come with the territory, which Dobrin pointed out was a “gray area” as well. The regulatory status of certain cryptocurrencies is unclear, where, if there were to be a sudden regulatory crackdown, it could make it difficult to sell these currencies or would even spur a plummet in prices. Besides, due to the lack of government assurances, sketchy coins accompanied by scammers do their rounds on the DeFi platform.</p><p>Max Unfried, scientific advisor at VitaDAO said: “Unfortunately, cryptocurrencies are still very much associated with scams. At the root of every biotech are scientists, and scientists are very skeptical people. While at least in the longevity space, VitaDAO has gathered the trust of the scientific community and overcome the initial skepticism other branches of science are yet to be convinced. While younger scientists especially at the postdoc and young PI level are more open to it, the scientific gerontocracy seems more skeptical.”</p><p>He also added that getting connected to the blockchain is still not as smooth, and that the user interface needs improvement.</p><p>While these concerns need tackling, calling for uniform international laws to regulate cryptocurrency — to prevent a collapse like that of FTX that occurred last year — Mirsky believes that communities like PharmaCollective.io are gaining traction in the biotech sector.</p><p>“They signify a move towards creating platforms that combine the principles of decentralized finance with the specific needs and goals of the biotech sector. Such platforms can act as intermediaries, guiding funds from investors to promising biotech projects in a transparent and decentralized manner.”</p><p>However, while this movement seems to be pressing forward, Unfried believes that it’s not meant to be a means for all biotechs to raise money, and is concentrated in underfunded, niche areas of research. As decentralized financing was created as an alternative to the current financial system, according to Unfried, he said: “The community is not much interested in the status quo, but more into biotechnologies that can be game changers — and change the world from sick care to true healthcare.”</p><p>“We are still at the beginning of the decentralized science and decentralized financing movement. Given it is still early, the total amount of funding that can be distributed by DAOs and other decentralized funding schemes is low in the grand total. While the available funding amount is going to increase over the next few years at the current state, it is probably most interesting for orphan and rare diseases that are overlooked by big pharma.”</p><p>As the cryptocurrency industry is poised to join the trillion dollar club in the next decade, according to Unfried, around 1% would typically be allotted toward biopharma projects. And, because of this influx of capital, “DeSci DAOs having $100 to $200 million would make them competitive and serious contenders in the biotech space.”</p><p>As startups like Matrix Biosciences spin out of DAOs, it could maybe drive more trust towards the DeFi movement. But how the young startup, and the healthcare DAO community at large, will fare, we will have to wait and see.</p><p><em>Disclaimer: The views, opinions, and analysis expressed are those of the author Sebastian Azar, and do not reflect or represent any policy or position of his employer, private or public institutions.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=32386709139e" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Decentralized clinical trials. Whats all about?]]></title>
            <link>https://medium.com/@Sebastian_Azar/decentralized-clinical-trials-whats-all-about-d6c39d35d68f?source=rss-764d1a0e5a13------2</link>
            <guid isPermaLink="false">https://medium.com/p/d6c39d35d68f</guid>
            <dc:creator><![CDATA[Sebastian Azar]]></dc:creator>
            <pubDate>Wed, 21 Jun 2023 07:21:39 GMT</pubDate>
            <atom:updated>2024-01-03T13:48:47.626Z</atom:updated>
            <content:encoded><![CDATA[<p>Major global pharmaceutical companies are introducing decentralized clinical trials (DCT) to reduce the drug development period, cut costs, and improve patient access to clinical trials.</p><p>However, Korea has yet to come up with a related regulatory regime, making the nation’s status disadvantageous as a participant in global clinical trials and resulting in a delay in introducing new drugs, according to concerned industry experts.</p><p>In a recent Bayer Pharma Media Day 2023, the multinational company also said it is making the most of DCO to develop its portfolios.</p><p>The purpose is to cooperate with partners and allow patients to participate in clinical trials more easily while enhancing diversification by lowering barriers to different demographic groups through DCT.</p><p>Christoph Koenen, senior vice president and head of Clinical Development &amp; Operations, Pharmaceutical Division, and Pharma R&amp;D, Bayer, talks about his company’s decentralized clinical trial plan during a recent media event.<br>“Bayer’s portfolio is based on up-to-date digital technology improved through new data and patient-oriented decentralized clinical trials,” said Christoph Koenen, senior vice president and head of Clinical Development &amp; Operations, Pharmaceutical Division, and Pharma R&amp;D, Bayer. “Such innovation will eventually expand patients’ access to clinical trials.”</p><p>He explained that Bayer is taking a mixed approach, in which the company does not entirely rely on DCT but mixes them with conventional clinical trials, adding that it is because various governments have different regulations in permitting DCT.</p><p>Koenen predicted that countries like Korea, which maintains a conservative position on DCT, will ultimately turn toward an open stance.</p><p>“If DCT is used more worldwide gradually, regulatory agencies will also understand the levels of data created by DCT are as high as those produced by traditional clinical trials,” he said. “If that happens, I expect the Korean regulators’ positions on DCT to turn more favorable, too.”</p><p>Bayer is not the only multinational pharma that has used DCT to develop new drugs. Other Big Pharma companies, such as GSK, AstraZeneca, Novartis, Pfizer, and Sanofi, have already been using DCT to develop their portfolios.</p><p>Companies in North America are most vigorously carrying out DCT, but other regions, including Asia-Pacific, Middle East, Africa, and Latin America, are also active in its use. The relevant fields are also diversifying, including the central nervous system, metabolic disorder, infection, respiratory system, tumor, and cardiovascular diseases.</p><p>In addition, the Covid-19 pandemic has sped up global pharma’s benefitting from DCT.</p><p>For instance, the number of DCTs stood at 207 worldwide in 2010, but the number increased to 1,011 in 2021 (refer to the graphic), and the upward trend will continue in the future, according to industry experts.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/600/0*oMFvNpUS0Dlvco_N.jpeg" /></figure><p>Regulators in various countries also moved actively to manage and support DCT, which drastically increased during the pandemic by, for instance, setting up guidelines.</p><p>In collaboration with contract research organizations and clinical trial sponsors, the U.S. Food and Drug Administration and other global regulatory agencies assessed DCT’s advantages and problems before determining standards for remote trials. In 2020, the FDA announced guidelines on clinical trials during the Covid-19 public health emergency period.</p><p>In December 2021, FDA also unveiled a draft guideline titled “Digital Health Technologies for Remote Data Acquisition in Clinical Investigations.”</p><p>However, Korea has yet to make regulatory rules on DCT. Moreover, experts point out that due to the Korean government’s viewpoint that regards clinical trials not as “research” but as “treatment,” it will not be easy to introduce DCT here.</p><p>The problem is the later the nation introduces DCT, the higher the likelihood it will be excluded from countries participating in global clinical trials, as DCT has already become a global trend.</p><p>may eventually lead to a delay in introducing new drugs. Usually, the Ministry of Food and Drug Safety first checks whether Korea participated in the landmark clinical trials of the drugs in question (whether there are Korean data) in reviewing them for approval.</p><p>To the relief of the industry, the government has taken its first step toward introducing DCT.</p><p>In the “Implementation plan for medicine products’ safety management” announced last month, the food and drug safety ministry said it would take a new approach to some elements of clinical trials, including collecting clinical data using wearables or mobile devices. In other words, the ministry has just rolled up its sleeves to work out DCT-related regulations.</p><p>Also, according to the government’s comprehensive plan to support the biopharmaceutical industry, it aims to rank third in global clinical trials by 2027 (from sixth in 2021) and is making detailed programs to foster DCT specialists.</p><p>“To nurture full-cycle experts equipped with clinical trials’ practical capabilities, we will foster talents in each stage of clinical trials, such as intermediary clinical trials, early and later trials, and overseas approval, while those in new areas, such as decentralized clinical trials,” the government said in the plan.</p><p><em>Disclaimer: The views, opinions, and analysis expressed are those of the author Sebastian Azar, and do not reflect or represent any policy or position of his employer, private or public institutions.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d6c39d35d68f" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The DeSci Movement: Will Crypto Really Solve Science’s Biggest Problems?]]></title>
            <link>https://medium.com/@Sebastian_Azar/the-desci-movement-will-crypto-really-solve-sciences-biggest-problems-22df1101ac3d?source=rss-764d1a0e5a13------2</link>
            <guid isPermaLink="false">https://medium.com/p/22df1101ac3d</guid>
            <dc:creator><![CDATA[Sebastian Azar]]></dc:creator>
            <pubDate>Wed, 21 Jun 2023 07:18:28 GMT</pubDate>
            <atom:updated>2023-06-21T07:18:28.408Z</atom:updated>
            <content:encoded><![CDATA[<h3>The DeSci Movement: Will Crypto Really Solve Science’s Biggest Problems?</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/959/0*FY1dCIvAeuQkBVqE" /></figure><p>An inefficient peer review process, the fact that renting a research paper for 48 hours can cost over $30, and the fact that scientists are spending more time applying for research grants than actually doing science are only some of the consequences of the greater problem of mismatched incentives among scientific research institutions around the world.</p><p>Amid the recent global pandemic, the blockchain and biotech communities looked to address these funding inequities and joined to start the Decentralized Science (DeSci) movement. Although it may still be hard to conceive of how diverse groups of people in Discord servers can change the game for scientific funding and publishing, it’s clear that blockchain’s inherent properties make an interesting case for why this could work.</p><h3>What does blockchain have to do with synbio?</h3><p>For a long time, blockchain’s applications in bio had been limited to securing data like genome analyses and medical records in an immutable and decentralized way. However, less than a decade after the creation of Ethereum, we can see DAOs leveraging NFTs and smart contracts to align people’s incentives and ultimately achieve a clear goal.</p><p>Now, in order to have a better understanding of how all this works, let’s first start with what this ubiquitous acronym means — DAO. It stands for Decentralized Autonomous Organization. Think Kickstarter on steroids: a group of people gather online to move the needle on a particular issue. Their mission is not to solve the problem themselves but to best support other people to do it. They “crowdfund” the DAO by issuing a type of coin (commonly known as a token) for the organization. Depending on the conditions under which the DAO operates, anyone who buys the token or contributes resources and work to the DAO can have a certain amount of decision power, like voting for which projects to fund.</p><p>The central thesis of biotech focused DeSci projects is that most biotech holding companies — or for that matter non-profit/governmental funds — aren’t interested in betting for risky projects at a small ticket size ($100–200k). Yet, if we want 10x more innovation as humanity, these are precisely the types of projects we cannot let get stuck, neither in the NIH grants valley of death nor in the VC catch-22 of needing funding to do science and needing science to get funding.</p><p>Biotech DAOs focus on helping these types of projects take aim at those moonshot ideas. In exchange, the DAO token holders get the power to govern the IP. For instance, how the IP is managed, how it’s licensed and how it’s commercialized. This is when NFTs become way more than just monkey pictures and start becoming certificates of ownership over something like a new method to<a href="https://discover.molecule.to/projects/clb0if1g001070fjqkxk01xmf"> scale up palm oil production</a> or a drug for a rare disease (to give a couple of examples).</p><p>Another hope for IP NFTs and DAOs — Paul Kohlhaas (cofounder of Molecule) notes — is that larger biotech companies can look through the portfolio of specific DAOs and even their patents. Then, if they happen to find anything interesting, they can either seek collaboration with the researchers and the DAO or look to license or buy the IP. The latter, in particular, would benefit everyone who took part in the process of creating that IP, including, of course, token holders.</p><p><a href="https://www.forbes.com/sites/carolschram/2023/06/20/whats-next-for-nhl-expansion-after-vegas-golden-knights-stanley-cup/?traffic_source=Connatix"><strong>What’s Next For NHL Expansion AfterVegas Golden Knights’ Stanley Cup?</strong></a></p><p><em>“While the market for these tools is not that large, owning a piece of the IP could be extremely valuable. There’s a sense of making history” — Niklas Rindtorff, cofounder of LabDAO</em></p><p>Moreover, what if even the seemingly failed projects could bring something to the table too? While traditional funding methods don’t encourage publishing disproved hypotheses, DeSci could make this information accessible to others to learn from previously attempted experiments.</p><h3>What are all those DAOs actually doing?</h3><p>After recent events in the crypto world, it’s fair to be skeptical about anything involving similar technology. But, at the same time, it’s fair to keep in mind that doing science itself, especially biotechnology, can be a process with very long iteration cycles.</p><p>That said, one of the best-known DAOs in the space is the longevity-focused VitaDAO, with more than 200 projects sourced, $3 million invested in research, and 1,300+ token holders, including Pfizer. Their token, $VITA, can be bought through cryptocurrencies like ETH at a market cap of $20 million.</p><p>The two projects listed on VitaDAO’s website started in April and June of this year, and both have a timeline of two years. The maximal returns for token-holders are still to be seen, but the DAO is already doing its job in sourcing projects, voting for them, and funding them.</p><p><em>“VitaDAO did something that Pfizer has been trying to do for years: create an open innovation ecosystem. Think of the bureaucracy inside Pfizer. This is the dawn of biotech DAOs — we’re only just getting started” — Paul Kohlhaas, cofounder and CEO of MoleculeDAO.</em></p><p>Now, not all of DeSci is about extending our lifespan. Take ValleyDAO, for instance, which was started this year by Albert Anis, a synthetic biologist, to address <em>planetary</em> health: to solve the existential threats of climate change and food security and ultimately create a fairer and more equitable bioeconomy. They’ll be minting their first IP-NFT in May this year which represents an ownership stake in the resulting IP from a funded research project at Imperial College London.</p><p>Molecule, on the other hand, is a decentralized biotech protocol. However, most importantly, it’s the marketplace for research-related IP. They developed IP-NFTs to connect academics and biotech companies with quick and easy funding, enabling patient, researcher, and investor communities to govern and own research-related IP directly. They work with DAOs like VitaDAO, ValleyDAO, PsyDAO (psychedelic medicine), and LabDAO (network of wet &amp; dry laboratory services).</p><p>Indeed, another goal of the DeSci movement is to fund projects previously neglected for being controversial, or not having a large enough market, or simply not being of interest to traditional funders (<em>see image below — curated by Jocelynn Pearl and Dani Elyse — for a more complete view of the DeSci landscape</em>).</p><p>For instance, Vibe Bio addresses the highly neglected problem of a lack of research in rare diseases. Cofounder Alok Tayi’s daughter was born with a rare disease, which pushed him to create a DAO that has now been backed by investors like Garry Tan (current YC president) and Balaji Srinivasan (former general partner at a16z and former CTO of coinbase). In addition, Vibe Bio provides an opportunity for parents and patients to fund the DAO according to their demands.</p><p><em>“Let patients decide what to get funded, not Wall Street” — Alok Tayi, founder of Vibe Bio</em></p><h3>Seeing beyond the walls</h3><p>First off, it’s fair to question how sustainable it is to join thousands of people, from all around the world, in a Discord server. Moreover, crypto has become famous among those who seek quick and easy money, so the question is: how serious could all these people be about solving biotech’s biggest problems? And more concretely, what if a specific group of investors accumulated major shares of DAO tokens and started to vote for things counter to the original goal? Where’s the promise for governance there?</p><p>Tyler Golato from Molecule reminds us that crypto is not the best place for independent thinking. “A lot of people use a DAO as an excuse for lack of governance,” he says. “However, we’re not building Molecule from a crypto perspective but from a meta-science perspective.” As a purist, he’s open to working on any solution that makes sense. Ultimately, what Molecule is really trying to do is focus on bringing drugs from academia to market.</p><p>Regarding ownership, the idea is to make different aspects of science (like peer review and grants) separate and specialized communities; in other words, make them decentralized. Still, there’s nothing preventing someone from buying out a whole DAO.</p><p>Now, all the DAOs and technologies mentioned thus far tend to generate a lot of data, and much of the DeSci movement would be all for naught if there weren’t a decentralized way to store that data. Well, thankfully, the InterPlanetary File System (IPFS) and Filecoin are two related technologies that aim to improve how digital content is stored and distributed. IPFS is a decentralized protocol for storing and sharing files, which allows users to access content based on its content address rather than its location on a specific server. This means that files can be distributed across a network of nodes, making it more resilient to censorship and improving performance by allowing faster and more efficient content delivery.</p><p>Filecoin is a blockchain-based storage network that incentivizes users to provide storage space for IPFS content by offering rewards in the form of Filecoin cryptocurrency. This creates a decentralized marketplace for storage, where users can buy and sell storage space, and content creators can pay for storage without relying on a centralized storage provider.</p><p>Ultimately, DeSci is one tool to align incentives in science, and the people involved in creating these tools will have to keep in mind what problem they’re solving and for whom. We couldn’t have put it better than James Sinka, cofounder of OrangeDAO:</p><p><em>“To give scientists more freedom to express their visions for the future and to tackle them — this reminds me of the ethos of Silicon Valley.”</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=22df1101ac3d" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Why having an innovation culture is so vital to the NHS’s longevity]]></title>
            <link>https://medium.com/@Sebastian_Azar/why-having-an-innovation-culture-is-so-vital-to-the-nhss-longevity-ff27f0dfe518?source=rss-764d1a0e5a13------2</link>
            <guid isPermaLink="false">https://medium.com/p/ff27f0dfe518</guid>
            <dc:creator><![CDATA[Sebastian Azar]]></dc:creator>
            <pubDate>Sun, 19 Mar 2023 06:50:04 GMT</pubDate>
            <atom:updated>2023-03-19T06:50:04.254Z</atom:updated>
            <content:encoded><![CDATA[<p>A great articles from Matt Whitty, Chief Executive of the Accelerated Access Collaborative and Director of Innovation, Research and Life Sciences, NHS England.</p><p>The NHS has a long-standing history of innovation since it was founded in 1948, which has been a crucial factor in transforming the healthcare industry. From pioneering procedures such as intra-ocular lens implants and total hip replacements, to critical technologies like computerised tomography (CT) and magnetic resonance imaging (MRI), the NHS has always been at the forefront of medical innovation. These innovations have not only transformed individual patient lives but have also brought significant benefits to the UK economy and society.</p><p>Innovation remains a cornerstone of the NHS, and it is now more important than ever before. The NHS is still facing ongoing pressures, but innovation is playing a crucial role in every aspect of our work. From operational pressures, increased demand to tackling health inequalities and improving outcomes, innovation is rising to the challenge, providing ground-breaking diagnosis and treatments.</p><p>Innovation in the NHS is purposeful and addresses real-world challenges and priorities facing society today. By focusing on areas that contribute most to early mortality, disability, and lost productivity in the UK, we can make the biggest impact on people’s lives.</p><p>Take Deep Medical, an artificial intelligence (AI)-driven technology on trial in Essex that has the potential to create over 100,000 additional hospital out-patient appointments per year. Founded by a frontline NHS doctor and a data scientist, Deep Medical collects non-personal data, including traffic information, weather forecasts, census data, and other data sources, to accurately predict the likelihood of a patient missing an appointment. It can then make tailored recommendations on actions to mitigate that possibility, harnessing the power of AI to support the workforce and deliver equitable access to care.</p><p>Ufonia is another innovative telemedicine platform helping to reduce elective backlogs by freeing up clinicians’ time. The tech replaces routine healthcare interactions with next generation automated phone calls. Now in use for cataract surgery follow-up across Oxford, Buckinghamshire and Frimley Park over 2000 patients have used the system with two thirds discharged utilising the AI triage technology.</p><p>Cytosponge is a diagnostic test on a string that speeds up the detection of patients at high risk of oesophageal cancer and can be used in acute or community settings. St Helens and Knowsley teaching hospital report that the product enabled them to clear their entire backlog of 300 patients awaiting endoscopies for Barrett’s oesophagus and they were able to bring patient appointments forward.</p><p>CanSense is an accurate, non-invasive, inexpensive blood test that uses an artificial intelligence-based model to diagnose bowel cancer early. The diagnostic tool can be used in primary care to stratify patients appropriately and rapidly, significantly reducing the need for invasive procedures, such as colonoscopy and speeding up the diagnosis of cancer.</p><p>All these innovations and hundreds more like them have been supported by the <a href="https://www.england.nhs.uk/aac/">Accelerated Access Collaborative (AAC)</a>, hosted by NHS England. One of NHS England’s missions has been to not only promote and encourage innovative and entrepreneurial thought but to also implement those ideas and help innovators navigate the system to achieve spread. The AAC is a vehicle for developing strategic partnerships between the NHS and industry to ensure a thriving health and life sciences and med-tech ecosystem that works for patients, society, and the economy.</p><p>As we celebrate the 75th anniversary of the NHS and the amazing innovations that have transformed healthcare, let’s continue to look forward and support the next generation of innovators. At NHS England, we remain committed to supporting the system to continue to nurture innovation. We believe that innovation is the key to transforming healthcare delivery and improving outcomes for patients. We will continue to support innovators in navigating the healthcare system and developing new solutions to address real-world problems.</p><p><a href="https://www.england.nhs.uk/blog/75-years-young-why-having-an-innovation-culture-is-so-vital-to-the-nhss-longevity/">https://www.england.nhs.uk/blog/75-years-young-why-having-an-innovation-culture-is-so-vital-to-the-nhss-longevity/</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=ff27f0dfe518" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Pfizer betting on De-Sci is a clear proof that change is happening.]]></title>
            <link>https://medium.com/@Sebastian_Azar/pfizer-betting-on-de-sci-is-a-clear-proof-that-change-is-happening-31ef5544ccb6?source=rss-764d1a0e5a13------2</link>
            <guid isPermaLink="false">https://medium.com/p/31ef5544ccb6</guid>
            <category><![CDATA[innovation]]></category>
            <category><![CDATA[pfizer]]></category>
            <category><![CDATA[desci]]></category>
            <category><![CDATA[zurich]]></category>
            <category><![CDATA[pharma]]></category>
            <dc:creator><![CDATA[Sebastian Azar]]></dc:creator>
            <pubDate>Wed, 15 Feb 2023 14:09:05 GMT</pubDate>
            <atom:updated>2023-02-15T14:09:05.889Z</atom:updated>
            <content:encoded><![CDATA[<h4>Following my latest article <a href="https://medium.com/@Sebastian_Azar/the-desci-landscape-its-evolving-as-you-read-this-article-8d4887ede7b4">“The DeSci Landscape: It’s evolving as you read this article.”</a>(1)</h4><p>It&#39;s happening in front of our eyes, almost tin silence.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*XRNwdoyW_khH68TZQzatWA.jpeg" /></figure><p>John Cumbers article Headline <a href="https://www.forbes.com/sites/johncumbers/2023/01/30/longevity-startup-vitadao-raises-41m-backed-by-pfizer-balaji-srinivasan/"><strong><em>Longevity Startup VitaDAO Raises $4.1m, Backed By Pfizer, Balaji Srinivasan</em></strong></a> (2) on Forbes went almost unnoticed. But this is a major bet in the De-sci world. One that should be talked by CTOs and Innovation leaders across the Pharma industry…. and still, everybody keeps boasting about the potential of Chat GPT or the Metaverse on Pharma.</p><p>Here are some of the highlights from the articles</p><p><strong><em>But </em></strong><a href="https://www.notboring.co/p/the-dao-of-daos#:~:text=A%20decentralized%20autonomous%20organization%20(DAO,rules%20enforced%20on%20a%20blockchain."><strong><em>what is a DAO</em></strong></a><strong><em>, really?</em></strong><em> It’s a new way to collectively finance, govern, and share value on the blockchain. Most communities start off as online collectives, congregating through chat apps such as Discord, which was originally popularized by online gaming communities. Each DAO server contains channels for various working groups; within VitaDAO, for instance, there are Deal Flow and Communications working groups, among others. Think of it like Reddit forums on steroids.</em></p><p>VitaDAO was started as an experiment in community-run research by Molecule, which announced their $12.7 million raise in June of 2022 (led by Northpond Ventures). Molecule hopes to turn science DAOs into a profitable business model, and has seeded several similar communities with different foci, including <a href="https://www.athenadao.co/">AthenaDAO</a>, which takes aim at women’s health research, and <a href="https://www.valleydao.bio/">ValleyDAO</a> which is broadly interested in synthetic biology.</p><p>So how Pfizer Ventures got into the mix?</p><p><em>Another contributor to the raise was Pfizer Ventures, the first instance of a pharma venture partner shaking hands with a DeSci organization. Pfizer representative Michael Baran, PhD, MBA (Executive Director and Partner, Pfizer Ventures) shared, “Pfizer has multiple partnering models to engage with biotech companies ranging from R&amp;D collaboration to equity investment. Translating academic science into the biotech space is often referred to as the valley of death, as many projects fail to find sufficient funding to advance. Decentralized Science caught our attention as an emerging area to address the valley of death challenge. We are excited to not only invest in but also actively participate in VitaDAO to explore this novel model to advance early stage science.”</em></p><p>Read the full article <a href="https://www.forbes.com/sites/johncumbers/2023/01/30/longevity-startup-vitadao-raises-41m-backed-by-pfizer-balaji-srinivasan/">here</a> and share your thoughts!</p><p>This article is part of the research Fun Pharma: How Innovation is making the Pharma Industry healthy people wants<strong><em>.</em></strong></p><ol><li><a href="https://medium.com/@Sebastian_Azar/the-desci-landscape-its-evolving-as-you-read-this-article-8d4887ede7b4">https://medium.com/@Sebastian_Azar/the-desci-landscape-its-evolving-as-you-read-this-article-8d4887ede7b4</a></li><li><a href="https://www.forbes.com/sites/johncumbers/2023/01/30/longevity-startup-vitadao-raises-41m-backed-by-pfizer-balaji-srinivasan/">https://www.forbes.com/sites/johncumbers/2023/01/30/longevity-startup-vitadao-raises-41m-backed-by-pfizer-balaji-srinivasan/</a></li></ol><p><em>Disclaimer: The views, opinions and analysis expressed are those of the author Sebastian Azar, and do not reflect or represent any policy or position of his employer, private or public institutions.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=31ef5544ccb6" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The DeSci Landscape: It’s evolving as you read this article.]]></title>
            <link>https://medium.com/@Sebastian_Azar/the-desci-landscape-its-evolving-as-you-read-this-article-8d4887ede7b4?source=rss-764d1a0e5a13------2</link>
            <guid isPermaLink="false">https://medium.com/p/8d4887ede7b4</guid>
            <dc:creator><![CDATA[Sebastian Azar]]></dc:creator>
            <pubDate>Wed, 28 Sep 2022 06:12:12 GMT</pubDate>
            <atom:updated>2022-09-28T06:12:12.906Z</atom:updated>
            <content:encoded><![CDATA[<p>I have been following the DeSci movement for over a year now, and I must say that the contributions of the community only get better and better.</p><p>In a world where Blockchain technology has been for better or worse popularised by crypto, DeSci is only growing stronger and stable.</p><p>Today I will share a few of the DeSci Landscapes built by those active members of the movement.</p><p><strong>Ultra Rare Bio</strong> created this fantastic (Yet to be updated) mapping of what&#39;s going on on the DeSci world https://twitter.com/ultrararebio</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Ov1xTyMyLjg56H5MPcHQNA.jpeg" /></figure><p><strong>Enlite AI </strong>has also produced a good screening on whats going on in Austria for blockchain <a href="https://www.enlite.ai/">https://www.enlite.ai/</a></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*p7opUcjo0JE4wHEIpoWq4g.png" /></figure><p>Fintech news reported an amazing visualization with the Blockchain initiatives in Switzerland <a href="https://fintechnews.ch/">https://fintechnews.ch/</a></p><p>Like previous editions, the CV VC Top 50 H2 2020 report names its selection of the Crypto Valley Top 50 companies. Out of the 50 companies, 24 focus on blockchain technology, providing services related to data and analytics, hardware and infrastructure, and platform and protocol; 22 are applying blockchain in financial use cases such asset management, crypto banking, and payment and stablecoins; and 4 use the technology in other areas including art, insurtech, media and supply chain. But no mention of DeSci. Pity.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/952/1*zUZy4nPn1xhBY2TbAfBvvQ.png" /></figure><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8d4887ede7b4" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>